Key Points
- Insider sale: Gregory Davis sold 69,827 shares on April 22 at an average of $0.25 for $17,456.75, cutting his ownership by 37.72% to 115,284 shares (about $28,821).
- Weak results and bearish sentiment: SGMO trades near $0.26 with a $105.6M market cap after missing quarterly expectations (EPS ($0.11) vs $0.01 expected; revenue $14.23M vs $40.25M expected), and analysts' consensus rating is "Reduce" with a $5.50 target amid mixed buy/hold/sell views.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) insider Gregory Davis sold 69,827 shares of Sangamo Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $0.25, for a total value of $17,456.75. Following the sale, the insider owned 115,284 shares of the company's stock, valued at approximately $28,821. This trade represents a 37.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Sangamo Therapeutics Trading Down 1.1%
Shares of SGMO opened at $0.26 on Friday. The firm has a fifty day moving average price of $0.34 and a 200-day moving average price of $0.44. The firm has a market capitalization of $105.64 million, a P/E ratio of -0.58 and a beta of 1.49. Sangamo Therapeutics, Inc. has a 12-month low of $0.21 and a 12-month high of $0.84.
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.12). Sangamo Therapeutics had a negative return on equity of 2,662.06% and a negative net margin of 310.81%.The company had revenue of $14.23 million during the quarter, compared to analysts' expectations of $40.25 million. Analysts predict that Sangamo Therapeutics, Inc. will post -0.17 earnings per share for the current year.
Analysts Set New Price Targets
SGMO has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Sangamo Therapeutics to a "strong sell" rating in a research note on Saturday, January 31st. Zacks Research downgraded Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday, April 16th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Reduce" and a consensus target price of $5.50.
Get Our Latest Stock Report on Sangamo Therapeutics
Institutional Investors Weigh In On Sangamo Therapeutics
Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Sangamo Therapeutics by 23.9% in the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company's stock worth $7,817,000 after purchasing an additional 2,240,422 shares during the period. Wasatch Advisors LP increased its holdings in Sangamo Therapeutics by 17.7% during the second quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company's stock valued at $4,376,000 after buying an additional 1,215,653 shares during the period. Geode Capital Management LLC increased its holdings in Sangamo Therapeutics by 17.6% during the fourth quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company's stock valued at $1,624,000 after buying an additional 579,550 shares during the period. GSA Capital Partners LLP raised its stake in Sangamo Therapeutics by 63.1% in the third quarter. GSA Capital Partners LLP now owns 3,662,478 shares of the biopharmaceutical company's stock worth $2,466,000 after buying an additional 1,417,029 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Sangamo Therapeutics by 182.7% in the third quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company's stock worth $1,669,000 after buying an additional 1,602,107 shares in the last quarter. Institutional investors own 56.92% of the company's stock.
Sangamo Therapeutics Company Profile
(
Get Free Report)
Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company's platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.
Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
